Background: The Charlson and Elixhauser comorbidity measures are commonly used methods to account for patient comorbidities in hospital-level comparisons of clinical quality using administrative data. Both have been validated in North America, but there is less evidence of their performance in Europe and in pooled cross-country data, which are features of the European Collaboration for Healthcare Optimization (ECHO) project. This study compares the performance of the Charlson/Deyo and Elixhauser comorbidity measures in predicting in-hospital mortality using data from five European countries in three inpatient groups. Methods: Administrative data is used from five countries in 2008-2009 for three indicators commonly used in hospital quality comparisons: mortality rates following acute myocardial infarction, coronary artery bypass graft surgery and stroke. Logistic regression models are constructed to predict mortality controlling for age, gender and the relevant comorbidity measure. Model discrimination is evaluated using c-statistics. Model calibration is evaluated using calibration slopes. Overall goodness-of-fit is evaluated using Nagelkerke's R 2 and the Akaike information criterion. All models are validated internally by using bootstrapping and externally by using the 2009 model parameters to predict mortality in 2008. Results: The Elixhauser measure has better overall predictive ability in terms of discrimination and goodness-of-fit than the Charlson/Deyo measure or the age-sex only model. There is no clear difference in model calibration. These findings are robust to the choice of country, to pooling all five countries and to internal and external validation. Conclusions: The Elixhauser list contains more comorbidities, which may enable it to achieve better discrimination than the Charlson measure. Both measures achieve similar calibration, so for the purpose of ECHO we judged the Elixhauser measure to be preferable.
Introduction
C ondition-specific hospital mortality rates are commonly used as indicators of health care quality. 1, 2 The European Collaboration for Healthcare Optimization (ECHO) project compares hospital quality within and between five European countries using a range of such indicators. In order to allow for meaningful comparisons, 3 it is essential to account for differing patient characteristics that might affect the probability of dying. 4 The most commonly used measures of comorbidities in health outcomes research are the Charlson measure (in its various adaptations) 5 and the Elixhauser measure. 6 Both are lists of medical conditions that can be constructed from the International Classification of Diseases (ICD) diagnosis codes as recorded in administrative datasets, and can in both cases be used to create a weighted index score to represent the severity of comorbidity. The aim of these measures is to capture the 'comorbidity burden' that exists alongside a primary diagnosis and that may influence health outcomes.
A number of studies have compared the performance of these two measures in different patient populations, including acute myocardial infarction (AMI), intensive care units, chronic renal failure, congestive heart failure, chronic obstructive pulmonary disease, acute cerebrovascular disease and colorectal cancer. [7] [8] [9] [10] [11] These studies have almost all been carried out in North America, with one in Taiwan. In general, these studies found the Elixhauser measure to outperform the Charlson measure, particularly in terms of discrimination (c-statistics).
It is unclear whether these findings can be transferred to a European setting and to the ECHO countries in particular. Furthermore, no study has investigated the predictive ability of the two measures in pooled data derived from different health-care information systems. These issues are highly relevant for the ECHO project, where health outcomes are compared within and across countries in Europe. These countries' health-care systems may differ in reimbursement mechanisms, coding practice and underlying epidemiology, all of which could affect levels of observed comorbidities and consequently predicted mortality.
The aim of this study is thus to determine the best comorbidity measure for the ECHO project, by comparing the performance of the Charlson/Deyo and Elixhauser measures with respect to their ability to predict in-hospital mortality in patient populations in five ECHO countries (Denmark, England, Portugal, Slovenia and Spain) and in pooled models of hospital quality performance. Three quality indicators are used: mortality after AMI, mortality after coronary artery bypass graft (CABG) surgery and mortality after stroke. We compare the measures with each other and with a model based on age and sex alone. The age/sex model serves as a benchmark using only information that is reliably and consistently coded across countries.
Methods

Data source
The ECHO data warehouse contains information on all publicly funded hospital admissions in the ECHO countries during the period 2002-2009, and is described in detail elsewhere in this special issue. 3 This study uses ECHO data for five countries (Denmark, England, Slovenia, Spain and Portugal) for three types of hospital admissions during the years 2008 and 2009. Detailed information is available on primary and secondary diagnoses, procedures, admission and discharge information, age, gender and whether the patient died in hospital.
Outcomes of interest
Previous research suggests that hospital safety and quality can have a significant impact on patient mortality and resource use. [12] [13] [14] [15] The Agency for Healthcare Research and Quality (AHRQ) developed a list of patient safety and hospital quality indicators based on inhospital mortality and other potentially preventable adverse events. 16 In this study, the chosen outcomes of interest are derived from the AHRQ inpatient quality indicators for CABG mortality rate (IQI#12), acute stroke mortality rate (IQI#17) and AMI mortality rate (IQI#15). Outcomes are constructed according to AHRQ definitions, except that patients transferred to another hospital provider are not excluded (as suggested by AHRQ) due to differences in clinical practice between some of the ECHO countries and the US setting. The ECHO data warehouse does not record out-of-hospital mortality as not all countries can link hospital records to death records. In-patient death at 30 days is therefore used as our measure of mortality, so patients who are discharged or who remain in hospital at 30 days are defined as 'survivors'.
Charlson/Deyo and Elixhauser
The most established list of comorbidities used in health outcomes research is the Charlson measure. 5 In this analysis, the Deyo et al. 17 adaptation is used, which has been the most commonly used adaptation and includes 17 conditions. More recent updated versions of the Charlson measure have retained fewer categories of comorbidity and revised the weights in the index. 18, 19 The Elixhauser measure was developed more recently 6 and includes a broader spectrum of 31 comorbidities. 6 The two comorbidity measures cover a range of similar medical conditions, with six comorbidity groups being coded identically.
Both measures are constructed following Quan's 2005 algorithm. 20 The comorbidity measures were created using ICD-9 codes in Portugal, Slovenia and Spain, and ICD-10 codes in England and Denmark. Previous research has found that the performance of both measures remains consistent and largely unaltered across ICD-9 and ICD-10 coding algorithms. 9 Both measures differentiate some comorbidities by level of severity. In cases where the patient record contains two or more codes that indicate different levels of severity of the same comorbidity, we retain only the code pertaining to the most severe level.
Analysis of predictive performance and model fit
Logistic regression is used to estimate the impact of comorbidities, as captured by each measure, on the probability of dying. All comorbidities are included as separate categorical variables, which has been shown to obtain the best model fit. 8, 21 Comorbidities that predicted the outcome perfectly or that described the cohort condition were excluded from the model. All models also include indicators of sex and age groups (categorized as 18-35, 36-40, 41-55, 56-60, 61-65, 66-70, 71-75, 76-80 and 81+) as any performance assessment based on comorbidities alone would lack face validity. We evaluated each model's individual and differential predictive performance according to three criteria 22, 23 : model discrimination, model calibration and goodness-of-fit. Model discrimination is the extent to which the prognostic model can distinguish individual patients who died from those who did not, and this was assessed by calculating the area under the Receiver Operating Characteristic curve (the c-statistic). 24, 25 A c-statistic of 0.5 suggests that the model discriminates no better than chance alone, and a c-statistic of 1.0 indicates perfect discrimination. Model calibration is the extent of agreement between observed outcomes and predictions. To assess model calibration, we examine the linear association between the observed mortality and the linear predictor using logistic regression models. 26 In a well calibrated model, the coefficient on the linear predictor, the calibration slope, should not be different from one. Goodness-of-fit is assessed in two different ways: First, we calculate the Nagelkerke R 2 statistic, which measures the proportion of variance that is explained by the model. 27 Larger values indicate better model fit. Second, we calculate the Akaike information criterion (AIC), which approximates the difference between the fitted model and the true underlying model based on information theory. 28 In contrast to measures based on R 2 , the AIC penalizes model complexity (i.e. the number of covariates included in the model) and is thus less likely to be subject to over-fitting. However, absolute AIC values are not directly interpretable and comparisons based on AIC can only be used to determine relative model fit.
To compare the different risk-adjustment models, we calculated the difference between each of the four metrics with associated 95% confidence intervals (CIs) using bootstrapping methods (see below). Differences were judged to be statistically significant if the confidence intervals did not include zero.
Internal and external validation
By design, logistic regression models compute the best event prediction for the sample data. However, high predictive ability in the estimation sample does not necessarily correspond to predictive power in independent samples and results may not be generalizable. All models are initially fitted to the 2009 data ('estimation sample'). To further validate model discrimination and the goodness-of-fit of these models and to guard against over-fitting, two validation exercises are conducted. 22, 23, 29 First, repeated random samples are drawn from the estimation sample (1000 iterations; with replacement), thereby creating new artificial datasets on which models are estimated. Based on these coefficient estimates, events are predicted in the estimation sample. Because the underlying pool of observations is the same, this bootstrapping approach only gives internal validation. For external validation the coefficient estimates from each bootstrap iteration are used to predict events in an independent dataset; the 'validation sample' for the previous year, 2008. It is important to note, however, that temporal variation can only validate the results within the same patient population and setting: it does not provide information about the transferability of findings to other settings or populations. 30 All statistical analyses were performed using Stata (StataCorp, College Station, Texas) version 12.
Results
Descriptive statistics and estimated odds ratios
The estimation sample comprises observations on 144 687 AMIs, 33 759 CABG procedures, and 129 653 strokes (table 1) . Crude 30-day inpatient mortality rates are 3.6% for CABG, 8.9% for AMI and 13.2% for stroke. The age and gender distribution appears well balanced across countries and conditions. In contrast, length of stay varies across countries for patients with similar conditions.
The number of Charlson comorbidities recorded in administrative records is generally lower than the number of Elixhauser comorbidities, due to differences in the number of conditions in each measure (17 
Model calibration checks show that most of the calibration slopes are not statistically different from one in the internal validation (see online supplementary material table S5). Poor calibration is apparent in the CABG sample and in some of the models estimated for Denmark and Slovenia. There were no clear differences between the two measures. Calibration appears to be significantly worse in the external validation.
Discussion
Our study compares the relative performance of the Charlson/Deyo and Elixhauser comorbidity measures with each other and with an age-sex only model in three patient populations (AMI, CABG and stroke) in five countries (Denmark, England, Portugal, Slovenia and Spain) and in these countries pooled. The findings indicate that in almost all comparisons the Elixhauser measure significantly outperforms the Charlson measure in terms of model discrimination and goodness-of-fit. Both measures have additional predictive power over a model that only accounts for age and sex in almost all comparisons (the exceptions being a small number of non-significant differences in small countries such as Denmark and Slovenia). There is little difference between the measures in terms of model calibration, although regression models based on the Elixhauser list of comorbidities are somewhat more suspect of miscalibration. These results are robust across countries and external validation. These findings are consistent with the results from previous studies that compared both measures for other conditions. 7, 11, 31, 32 This study contributes to the existing literature in several ways. First, while the Charlson and Elixhauser measures have been developed and widely validated using American and Canadian administrative datasets, to our knowledge this is the first published study to test their relative performance using comparative European hospital discharge data. There is increasing interest in comparing the performance of different health-care systems and individual institutions across Europe. Researchers have begun to study variation in hospital performance, 3 efficiency 33 and equity of access to care. 34, 35 In order to allow for meaningful comparison, outcome measures need to be risk-adjusted to account for differences in patient populations.
The second contribution results from the use of both internal and external validation of the predictive ability of the estimated riskadjustment models. In estimating and testing a predictive model on the same dataset, there is a danger that the model is 'over-fitted' (i.e. the coefficients are specific to the observed data and exaggerate random fluctuations observed in some of the (17) 15 (14) 21 (27) 12 (14) 18 (20) 13 (19) 11 (19) 16 (22) Inpatient LOS >30 days (%) (14) 69 (13) 68 (13) 70 (13) 69 (13) 70 (13) 68 (10) 66 (10) 68 (9) 68 (9) 68 (10) 68 (10) 75 (13) 74 (12) 73 (12) 70 (14) 75 (13) 75 (13) Male gender (%) a: In Denmark and England hospital stays (admission to discharge) can consist of multiple 'episodes' so there is no theoretical limit on the number of diagnosis fields. The ECHO data warehouse is designed to record up to 48 comorbidity codes. Dx, diagnosis; Dx2, secondary diagnosis.
variables). In this situation, the model will describe the relationship between outcome and independent variables for the given sample well but it is likely to predict poorly in an independent sample. Several studies that compare the Charlson and Elixhauser measures have only validated their results on re-sampled datasets where observations were randomly drawn from the same sample on which the coefficients were estimated. This internal validation can help detect the effect of unusual comorbidity-outcome combinations in the estimation sample, but does not allow any conclusions to be drawn about predictive performance in independent samples, such as consecutive patient cohorts. In this analysis, external validation was conducted using data on inpatients in all countries in the year preceding the estimation study period. This is not a perfect independent sample-using another country or another domain (if such data were available to us) would have added value to our external validation-but it nevertheless provides some reassurance. 28 The results suggest that the predictive ability of the estimated model is high in an independent dataset, albeit somewhat lower than in the original dataset. The comparative advantage of the Elixhauser measure over the Charlson measure is reflected in both internal and external validation.
The third contribution is the direct comparison of performance for different patient populations within the same study. We chose three AHRQ quality indicators to define the patient population under study and the relevant outcome measure. All three indicators are widely used in the US health-care system to compare hospital performance, and they form the basis for hospital comparisons in the ECHO project (see the article on Spain-England hospital comparison in this issue). By comparing predictive ability in three different patient populations within the same study, the comparability of the analytical approach, as well as data extraction, estimation and interpretation, is ensured.
A number of limitations of our analysis remain. First, there exist many more comorbidity measures and more modifications of the two measures we chose. Newer versions of the Charlson comorbidities 18, 19 have reduced the list of conditions compared with the Deyo adaptation. This could potentially improve the performance of models like ours in terms of parsimony and avoiding over-fitting, and it would be useful to include these refined measures in future comparisons of this sort. In addition, it is important to note that we used the two sets of comorbidities as lists-with binary variables indicating the presence or absence of a condition-rather than using an index score. This is partly to retain detail and flexibility, and partly as some research has recommended this practice to better predict mortality. 21 Second, we are well aware of the complexities and difficulties of comparing hospitals across countries, in particular the scope for differences in coding practice. As illustrated in table 1, the five countries in this sample use two different diagnosis coding systems (ICD-9 and ICD-10) and vary in terms of the number of diagnoses that can be included in any episode. There were some apparent differences in coding between countries that may have influenced our findings.
The explicit aim of this study was to compare the performance of two existing and widely used comorbidity measures in predicting mortality in patients in the ECHO countries, with the ultimate aim of conducting comparisons of outcomes across hospitals or regions as part of the ECHO project. Although our results have broad appeal and may contribute to the general understanding of the performance of comorbidity measures, we did not seek to generate prediction rules that can be used in clinical practice to predict the risk of prospective patients. We also warn against using the estimated coefficients as weights to adjust for case-mix differences in other countries or patient populations. Further research is needed to establish whether the relative performance of these measures holds for other patient populations outside the area of cardiovascular disease, and to investigate the underlying reasons for differences in comorbidity prevalence rates across countries (e.g. differential coding) as well as differences in the odds ratios associated with certain comorbidities.
The purpose of adjusting for comorbidities when using individual condition indicators, as in the ECHO project, is to make meaningful comparisons. The findings of this analysis, along with previous research, suggest that for this purpose, the Elixhauser measure is judged to be a good choice. 
Key points
There is variation in the predictive ability of the Charlson/ Deyo and Elixhauser comorbidity lists to explain 30-day inpatient mortality across five European countries (England, Portugal, Slovenia, Denmark and Spain) and three patient groups (acute myocardial infarction, bypass graft surgery and stroke). Risk-adjustment models based on the Elixhauser list of comorbidities outperform those based on the Charlson list in most settings, and never perform statistically significantly worse. None of the models explains more than 20% of variation in outcome. The Elixhauser comorbidity index appears preferable for risk-adjustment in European Collaboration for Healthcare Optimization's comparisons of hospital performance.
